Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ups and downs--and ups in the antiviral therapy of HIV infection.

× No keyword cloud information.

20 in total

1. Time to hit HIV, early and hard.

Authors: D D Ho
Journal: N Engl J Med Date: 1995-08-17 Impact factor: 91.245

2. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.

Authors: J P Aboulker; A M Swart
Journal: Lancet Date: 1993-04-03 Impact factor: 79.321

3. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Authors: D A Cooper; J M Gatell; S Kroon; N Clumeck; J Millard; F D Goebel; J N Bruun; G Stingl; R L Melville; J González-Lahoz
Journal: N Engl J Med Date: 1993-07-29 Impact factor: 91.245

4. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors: J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal: N Engl J Med Date: 1992-08-27 Impact factor: 91.245

5. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

Authors: J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; G M Dickinson; G L Drusano; M J Egorin; W L George; F M Gordin
Journal: N Engl J Med Date: 1992-02-13 Impact factor: 91.245

6. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors: M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245

7. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.

Authors: P M Mannucci; A Gringeri; G Savidge; P Gatenby; Y Laurian; I Pabinger-Fasching; J M Martinez-Vazquez; E W Hessey; H M Steel
Journal: Br J Haematol Date: 1994-01 Impact factor: 6.998

8. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors: M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal: Ann Intern Med Date: 1990-05-15 Impact factor: 25.391

9. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.

Authors: W R Lenderking; R D Gelber; D J Cotton; B F Cole; A Goldhirsch; P A Volberding; M A Testa
Journal: N Engl J Med Date: 1994-03-17 Impact factor: 91.245

10. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors: D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal: N Engl J Med Date: 1994-03-10 Impact factor: 91.245

1 in total

1. The Medication Attribution Scale: perceived effects of antiretrovirals and quality of life.

Authors: S Aversa; C Kimberlin; R Segal
Journal: Qual Life Res Date: 1998-04 Impact factor: 4.147

1 in total